Therefore, the goals of this study were (a) to confirm plasma concentrations of different EV subtypes originating from activated endothelial cells, platelets, leukocytes, pericytes, TF-bearing, and nucleoprotein (NP) SARS-CoV-2-bearing, as well as EV-associated procoagulant activity in patients hospitalized for COVID-19, and (b) evaluate the longitudinal trend of EV subtypes at discharge and 30 days post-discharge. This evidence concerns the gene TF and COVID-19.